Skip to content
2000
Volume 5, Issue 2
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The discovery of the key negative regulator MDM2 (mouse double minute 2, also termed HDM2 for its human equivalent) provided a great opportunity to manipulate the levels of the tumor suppressor p53 in cancer cells. Activation of p53 in tumor cells by inhibiting the interaction of MDM2 with p53 has therefore been the focus of a large effort in drug discovery. The modulation of protein-protein interactions, however, has historically been very difficult to achieve owing to the large surface area of interaction. In this article, we review the recent accomplishments in this area and our quest for a clinically viable MDM2 inhibitor.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026053507705
2005-04-01
2025-05-12
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026053507705
Loading

  • Article Type:
    Review Article
Keyword(s): mdm2; p53; peptidic inhibitor; protein-protein interaction; small molecule inhibitor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test